KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Lifitegrast ophthalmic solution 5.0% (KH732) for dry eye disease: A randomized, multicenter, double-masked, vehicle-controlled phase 3 trial.

Yang Lu, Xiuming Jin, Xiaofeng Li, Ying Jie, Liming Tao, Shengwei Ren, Shaozhen Zhao, Ying Li, Guoxing Xu, Wenjuan Zhuang, Ying Li, Wei Chen, Shanjun Cai, Hao Gu, Hong Zhang, Lan Li, Zhipeng You, Jianqiao Li, Jiangyue Zhao, Qi Chen, Ting Huang, Pengcheng Wu, Ting Wang, Yong Yao, Hua Wang, Zhuo Li, Xiangwen Shu, Ruifeng Wang, Mingchang Zhang, Feng Wen, Yao Fu, Cheng Pei, Wei Zhang, Huaijin Guan, Hui Zhao, Jizhong Yang, Lin Song, Min He, Xingxiang Lv, Fusheng Wu, Lan Gong, Xinghuai Sun

Ocul Surf 41 45-53

PMID42069335
PMCID-
DOI10.1016/j.jtos.2026.04.006
发表日期2026-05-02
入排依据:未发现恶性肿瘤人群证据。
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: Dry eye disease (DED) commonly impairs quality of life. This phase 3, randomized, double-masked, multicenter, vehicle-controlled trial evaluated the efficacy of 5.0% lifitegrast ophthalmic solution (KH732) in improving signs and symptoms of DED. METHODS: Adults with moderate-to-severe DED and corneal staining score ≥2.0 in any corneal region were randomized 1:1 to lifitegrast (KH732) or vehicle twice daily for 84 days after a 3-7-day vehicle washout. The primary endpoint was change from baseline in inferior corneal staining score (ICSS) at Day 84. Secondary endpoints included changes in total corneal staining score, Eye Dryness Score (EDS), Ocular Surface Disease Index (OSDI), 7-item visual analogue scale, and Ocular Discomfort Score. RESULTS: At Day 84, lifitegrast (n = 309) significantly reduced ICSS versus vehicle (n = 306) (P = 0.027). In a post hoc analysis, the effect was more pronounced in participants with the highest baseline staining in the inferior region (P = 0.046). Lifitegrast also significantly improved EDS (adjusted P = 0.006), ocular discomfort (adjusted P = 0.010), photophobia (adjusted P = 0.004), and OSDI (adjusted P = 0.014) versus vehicle. Post hoc analyses showed significant between-group differences in EDS, photophobia, and OSDI as early as Day 14. No serious ocular adverse events were reported. CONCLUSIONS: Lifitegrast (KH732) improved both signs and symptoms of DED and was generally well tolerated, with potentially greater benefit in patients with prominent inferior corneal staining.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。